UPDATE: Jefferies Starts POINT Biopharma Global Inc. (PNT) at Hold

July 27, 2021 4:05 AM EDT
Get Alerts PNT Hot Sheet
Price: $10.07 +5.56%

Rating Summary:
    2 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 3 | New: 7
Trade Now! 
Join SI Premium – FREE
(Updated - July 27, 2021 7:43 AM EDT)

Jefferies analyst Chris Howerton initiates coverage on POINT Biopharma Global Inc. (NASDAQ: PNT) with a Hold rating and a price target of $8.00.

The analyst commented, "Radiopharmaceuticals have been promising therapies, but difficult CMC/logistics have hampered commercial adoption. We like PNT's optimized CMC capabilities to address these challenges, but see value as short-lived and clin. programs un-differentiated from NVS (Buy) that are years ahead. We exp. lead asset '2002 approved in mCRPC but w/ limited adoption due to competition. Key catalyst is Ph3 '2002 data for mCRPC in '23. Initiate at Hold w/ a 12-month PT of $8."

For an analyst ratings summary and ratings history on POINT Biopharma Global Inc. click here. For more ratings news on POINT Biopharma Global Inc. click here.

Shares of POINT Biopharma Global Inc. closed at $8.82 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co